中国人民解放军总医院（301医院）创建于1953年，是集医疗、保健、教学、科研于一体的大型现代化综合性医院，直属于中国人民解放军联勤保障部队。医院是中央重要保健基地，承担军委、总部等多个体系单位、官兵的医疗保健和各军区、军兵种转诊、后送的疑难病诊治任务。医院同时又是解放军医学院，以研究生教育为主，是全军唯一一所医院办学单位。 据医院官网2015年12月信息显示，医院设置165个临床、医技科室，233个护理单元，拥有8个国家重点学科、1个国家重点实验室、20个省部级及全军重点实验室、33个全军医学专科中心和研究所，形成了以综合诊疗为特色的13项专业优势。同时是全军重症监护示范基地和中华护理学会的培训基地。设有国际医学中心和健康医学中心，提供高端预防保健服务。医院年门急诊量490余万人，收容19.8万人，手术近9万例。 医院拥有5位中国工程院院士，1百多名技术三级以上专家，1千多名高职专业技术人员。医院先后获得省部级以上科技成果奖励1300余项，其中，国家科技进步一等奖7项，二等奖20项，国家发明奖2项，军队科技进步一等奖21项。 2017年11月11日下午，复旦大学医院管理研究所正式发布了《2016年度中国医院排行榜》和《2016年度中国医院专科声誉排行榜》，中国人民解放军总医院名列第三。
The endoplasmic reticulum (ER) and mitochondria are critical organelles in maintaining cellular homeostasis and regulating cell fate. However, current biological and chemical approaches for modulating ER and mitochondrial functions often lack specificity and spatiotemporal controllability, potentially leading to off-target or systemic effects that limit their clinical applications. Here, by synthesizing a physical stimulus-based acoustoelectric nanoregulator, barium zirconate titanate (BZT) nanoparticles (NPs) with enhanced piezoelectric properties, we aimed to modulate ER and mitochondrial functions by regulating intracellular concentrations of calcium ions (Ca2+) and hydrogen ions (H+), thereby enabling spatiotemporally controllable modulation of cell fate. BZT NPs significantly modulated calcium ion dynamics and pH in tumor cells under ultrasound stimulation, accompanied by perturbations in ER and mitochondrial homeostasis, induction of ER stress and mitophagy, and ultimately alterations in cell fate. In the tumor-bearing mouse model, the acoustoelectric nanoregulator spatiotemporally modulates the intracellular environment through electrical signaling and ionic dynamic modulation under ultrasound stimulation, expanding the application prospects of physical stimulation-based strategies for abnormal cell function regulation. Our findings provide fresh perspectives for understanding cellular stress responses and cell fate determination processes, and lay the foundation for developing novel interventions in precision therapy and cell engineering applications.
Abstract The liver is the primary target organ for hematogenous metastasis of colorectal cancer, and colorectal cancer liver metastasis is one of the key and challenging aspects in its treatment. In order to improve the diagnosis and comprehensive treatment of colorectal cancer liver metastasis, the guideline development group has summarized advanced experiences and the latest achievements from both domestic and international sources, and has once again revised and updated the Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastases (2025 edition) to continuously provide guidance and reference for clinical practice in this field.
The emergence of targeted therapies against the epidermal growth factor receptor (EGFR) has transformed the treatment landscape for metastatic colorectal cancer (mCRC). However, the absence of methodologies capable of dynamically monitoring drug-target engagement and subsequent molecular responses at high sensitivity represents a critical translational gap, impeding personalized treatment adaptation. Here, we report an integrated nanoscale sensing platform that synergizes a high-quality-factor (high-Q) Terahertz (THz) metasensor with modularly engineered exosome-targeting theranostic probe (Exo-TTprobe) for ultrasensitive, longitudinal evaluation of targeted therapy efficacy. By exploiting exosomes as natural nanocarriers of membrane-bound drug-target complexes, our system achieves specific detection through a dual amplification strategy combining rolling circle amplification (RCA) and gold nanoparticle-enhanced THz transmission shifts. The platform exhibits exceptional sensitivity with a detection limit of 103 particles/ml across a dynamic range spanning 103 to 108 particles/ml, enabling discrimination of heterogeneous EGFR expression and drug response in cetuximab-sensitive and non-sensitive CRC cell lines within hours of cetuximab exposure. Most notably, in a clinical cohort of 15 mCRC patients, we successfully captured therapy-specific molecular signatures directly from plasma-derived exosomes, identifying statistically significant differential signals within 12 h of targeted therapy, which further intensified by 24 h. Compared to traditional imaging evaluation, our method has the potential for early assessment of targeted therapy and adaptation to precision medicine. This work establishes a transformative paradigm for real-time, molecular-level monitoring of targeted therapeutics, with broad potential applicability across diverse oncogenic drivers and cancer types.
This study aims to evaluate the efficacy of large language models (LLMs) in health management for urological and andrological conditions by comparing two Chinese LLMs: DeepSeek and Kimi. The responses of DeepSeek and Kimi to 30 questions on six urological and andrological diseases were quantitatively assessed using quality assessment tools, expert assessments, and readability metrics. In quality assessments, DeepSeek outperformed Kimi in only two instances: responses to "What are the surgical options for kidney stones?" (PEMAT-AI: P = 0.012; DISCERN-AI: P = 0.024) and "What are the treatment modalities for bladder cancer?" (PEMAT-AI and DISCERN-AI: P < 0.001). Expert assessments revealed that DeepSeek demonstrated superior accuracy and safety compared to Kimi only in addressing "Dietary considerations for kidney stone patients" (accuracy: P < 0.001; safety: P = 0.02). No statistically significant differences were found in quality assessments or expert assessments between the models for disease-specific categories. However, Kimi outperformed DeepSeek in readability evaluations. Both DeepSeek and Kimi exhibit substantial efficacy and clinical applicability in managing urological and andrological diseases. To enhance their practical use, Kimi requires improvements in accuracy and safety, while DeepSeek should focus on improving readability.
Patients with unresectable large HCC may be downstaged through TACE followed by MWA to achieve curative treatment. Controversially, for some patients, single MWA treatment may be sufficient. This study aimed to evaluate the clinical outcomes of unresectable large HCC treated with transarterial chemoembolization (TACE) followed by microwave ablation (MWA) and compare them based on the tumor burden score (TBS), to provide a scientific basis for guiding treatment strategies. This retrospective study included 294 patients with unresectable large HCC (449 tumors) treated with MWA between January 2010 and June 2023 at the General Hospital of the People’s Liberation Army. Propensity score matching (PSM) was used to compare the TACE sequential MWA group (n = 103) with the single MWA group (n = 103). The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS) and occurrence of adverse events. Subgroup analyses were conducted by identifying TBS split points using the interaction cubic spline plot method. Among the 294 patients, 76.5
